Bexion Pharmaceuticals Announces the Opening of Phase I Part 3 FOR IMMEDIATE RELEASE Covington, KY ~ February 22, 2019 - Bexion Pharmaceuticals, Inc. (Bexion) announced today the opening of Part 3 of their Phase I First-In-Human [...]
FOR IMMEDIATE RELEASE Covington, KY, February 22, 2019 - Dr. Ray Takigiku, Founder and CEO of Bexion Pharmaceuticals, Inc. was honored as a finalist in the category of “Entrepreneur” of the Year by the Cincinnati Business [...]
FOR IMMEDIATE RELEASE Covington, KY, November 19, 2018 - Bexion Pharmaceuticals, Inc., a clinical - stage biopharmaceutical company focused on rare brain and solid tumors, announced today that a clinical oral report followed by poster [...]
Bexion Pharmaceuticals is developing innovative cures for cancer.
Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.
In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).
Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857